Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy-evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO).

Vehreschild, J J; Böhme, A; Cornely, O A; Kahl, C; Karthaus, M; Kreuzer, K-A; Maschmeyer, G; Mousset, S; Ossendorf, V; Penack, O; Vehreschild, M J G T; Bohlius, J (2014). Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy-evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO). Annals of oncology, 25(9), pp. 1709-1718. Oxford University Press 10.1093/annonc/mdu035

[img]
Preview
Text
Vehreschild AnnOncol 2014.pdf - Published Version
Available under License Publisher holds Copyright.

Download (196kB) | Preview

BACKGROUND

Current evidence on myelopoietic growth factors is difficult to overview for the practicing haematologist/oncologist. International guidelines are sometimes conflicting, exclude certain patient groups, or cannot directly be applied to the German health system. This guideline by the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Medical Oncology (DGHO) gives evidence-based recommendations for the use of G-CSF, pegylated G-CSF, and biosimilars to prevent infectious complications in cancer patients undergoing chemotherapy, including those with haematological malignancies.

METHODS

We systematically searched and evaluated current evidence. An expert panel discussed the results and recommendations. We then compared our recommendations to current international guidelines.

RESULTS

We summarised the data from eligible studies in evidence tables, developed recommendations for different entities and risk groups.

CONCLUSION

Comprehensive literature search and expert panel consensus confirmed many key recommendations given by international guidelines. Evidence for growth factors during acute myeloid leukaemia induction chemotherapy and pegfilgrastim use in haematological malignancies was rated lower compared with other guidelines.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine (ISPM)

UniBE Contributor:

Bohlius, Julia Friederike

Subjects:

600 Technology > 610 Medicine & health
300 Social sciences, sociology & anthropology > 360 Social problems & social services

ISSN:

0923-7534

Publisher:

Oxford University Press

Language:

English

Submitter:

Doris Kopp Heim

Date Deposited:

01 Apr 2015 11:10

Last Modified:

02 Mar 2023 23:26

Publisher DOI:

10.1093/annonc/mdu035

PubMed ID:

24631945

Uncontrolled Keywords:

G-CSF, cancer, evidence-based guideline, febrile neutropenia, infection, supportive care

BORIS DOI:

10.7892/boris.65611

URI:

https://boris.unibe.ch/id/eprint/65611

Actions (login required)

Edit item Edit item
Provide Feedback